Zhou H, Dai Y, Zhu L, Wang C, Fei X, Pan Q, et al
. Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC. J Int Med Res. 2016;44:89-98 pubmed publisher
..Tumour expression level of BRCA1 was positively correlated with survival duration. KRAS mutation status and BRCA1 tumour expression are potential biomarkers for tailoring chemotherapy and predicting clinical outcome. ..